Mark Andrew Wilson's Insider Trades & SAST Disclosures
Mark Andrew Wilson's most recent trade in Nektar Therapeutics was a trade of 9,996 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on May 19, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Andrew Wilson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 19 May 2025 | 9,996 | 314,296 (0%) | 0% | 0.7 | 6,697 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Feb 2025 | 11,040 | 324,292 (0%) | 0% | 1.0 | 11,150 | Common Stock |
| Nektar Therapeutics | Mark Wilson Andrew | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.90 per share. | 23 Dec 2024 | 33,402 | 351,892 (0%) | 0% | 0.9 | 30,062 | Common Stock |
| Nektar Therapeutics | Wilson Mark Andrew | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 23 Dec 2024 | 16,560 | 335,332 (0%) | 0% | 0.9 | 14,738 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 331,875 | 331,875 | - | - | Stock Option | |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 325,000 | 325,000 | - | - | Stock Option | |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 165,938 | 385,294 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Nov 2024 | 6,407 | 218,856 (0%) | 0% | 1.0 | 6,471 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 19 Aug 2024 | 5,651 | 225,263 (0%) | 0% | 1.3 | 7,233 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 17 May 2024 | 6,260 | 230,414 (0%) | 0% | 1.8 | 10,955 | Common Stock |
| Nektar Therapeutics | Wilson Andrew Mark | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 20 Feb 2024 | 7,606 | 236,674 (0%) | 0% | 0.7 | 5,172 | Common Stock |
| Nektar Therapeutics | Andrew Wilson Mark | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 325,000 | 325,000 | - | - | Stock Option | |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 16 Aug 2023 | 7,221 | 250,959 (0%) | 0% | 0.8 | 5,632 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.72 per share. | 16 May 2023 | 7,543 | 257,680 (0%) | 0% | 0.7 | 5,431 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 16 Feb 2023 | 8,275 | 265,223 (0%) | 0% | 3 | 24,825 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 331,875 | 331,875 | - | - | Common Stock | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 165,938 | 284,377 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 4.76 per share. | 15 Aug 2022 | 3,189 | 281,188 (0%) | 0% | 4.8 | 15,180 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 16 May 2022 | 3,136 | 117,939 (0%) | 0% | 3.9 | 12,387 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 16 Feb 2022 | 3,661 | 121,075 (0%) | 0% | 11.0 | 40,088 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 67,150 | 67,150 | - | - | Stock Option | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 37,800 | 124,736 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 20,100 | 93,000 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 15 Nov 2021 | 6,564 | 86,436 (0%) | 0% | 13.2 | 86,382 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 35,800 | 35,800 | - | - | Stock Option | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 16 Aug 2021 | 1,910 | 72,900 (0%) | 0% | 13.8 | 26,415 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 17 May 2021 | 1,917 | 74,810 (0%) | 0% | 18.3 | 35,081 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 22.37 per share. | 16 Feb 2021 | 2,173 | 76,727 (0%) | 0% | 22.4 | 48,610 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 03 Feb 2021 | 5,344 | 78,900 (0%) | 0% | 19.5 | 103,941 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 5,344 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 03 Feb 2021 | 5,344 | 84,244 (0%) | 0% | 8.8 | 47,027 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 51,000 | 51,000 | - | - | Stock Option | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 28,550 | 78,900 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 16.93 per share. | 16 Nov 2020 | 1,539 | 49,850 (0%) | 0% | 16.9 | 26,055 | Common Stock |
| Nektar Therapeutics | Mark Andrew Wilson | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 19.67 per share. | 17 Aug 2020 | 1,529 | 51,389 (0%) | 0% | 19.7 | 30,075 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges